TX-TQ-DELTA
30.5.2019 00:13:05 CEST | Business Wire | Press release
TQ Delta LLC, a technology development and licensing firm, secured another favorable judgment last week when a Delaware federal jury found that 2Wire Inc. infringed three of TQ Delta’s patents related to Digital Subscriber Line (“DSL”) technology. 2Wire is a subsidiary of ARRIS Solutions, which was recently acquired by CommScope Inc.
TQ Delta’s patents cover important memory sharing capabilities for DSL modems and central office equipment, among other inventions. TQ Delta notes that these inventions are widely employed not just in the United States, but around the world.
This ruling represents another victory for TQ Delta’s ongoing licensing business. Earlier this year, the High Court of Justice of England and Wales also found in favor of TQ Delta on another patent from its deep portfolio of DSL inventions. The UK Proceeding against ZyXEL Communications UK Ltd and its Danish parent company, ZyXEL Communications A/S (both subsidiaries of Unizyx Holding Corporation) found TQ Delta’s European Patent (UK) 1 453 268 valid and infringed, as well as essential to the standards for ADSL2 and VDSL2. The Court granted an immediate injunction and award of costs against the ZyXEL defendants. ZyXEL defendants have appealed some elements of the judgment and that appeal is pending. TQ Delta’s worldwide portfolio spans a broad range of standard essential patents (“SEPs”) and non-SEPs that are central to key broadband network technologies. In addition to validation by courts in the US and UK, TQ Delta has successfully licensed its technology to key market participants.
The most recent verdict was announced on May 23 following a nearly four-day trial in the United States District Court for the District of Delaware. After deliberation, the eight-member jury returned a favorable verdict on all eleven counts, finding that 2Wire infringed U.S. Patent nos. 7,836,381, 7,844,882 and 8,276,048, that those patents were not obvious over prior art, and that two certificates of correction were not invalid.
“We are pleased with the jury’s decision affirming the strength and importance of our portfolio of inventions, which are the culmination of years of investment in standards development and communications technologies,” said Abha Divine, Managing Director of TQ Delta.
TQ Delta has supported continued development of DSL markets by maintaining a longstanding business strategy designed to ensure advancements in the technology. “The TQ Delta portfolio and continued investment in the field contributes to the past, present, and future of high-speed DSL connections around the world. We have already licensed several companies to practice the important inventions under our DSL portfolio and will continue to seek to license others through business negotiations,” said Divine.
TQ Delta was represented by McAndrews, Held, and Malloy, Ltd., a firm specializing in intellectual property prosecution, counselling, and dispute resolution.
Lead trial attorney, Peter McAndrews, explained that “The Defendant’s strategy was to trivialize the important inventions at issue. We are pleased that the jury vindicated the inventors’ hard work and our client’s commitment to innovation.”
TQ Delta maintains a sizable patent portfolio for digital communication technology, including DSL.
About TQ Delta
TQ Delta is a technology development and licensing company aimed at providing needed solutions for the communications industry and beyond. The company’s technical investments span nearly two decades of contributions and innovation in the field of communications. TQ Delta’s technologies are used in leading products and services worldwide spanning broadband communications and media distribution. For more information, visit http://www.tqdelta.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190529005990/en/
Contact:
Scott Krady Magnitude, Inc. scott@magnitudegrowth.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release
Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release
Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release
Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
